文献速递膀胱癌与上尿路尿路上皮癌

蓝光与白光经尿道切除术治疗非肌层浸润性膀胱癌:一项简略的Cochrane系统评价

Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review.
PubMed 文献 · BJU Int · 2022-04-06

该Cochrane系统评价纳入16项随机对照试验共4325例非肌层浸润性膀胱癌患者,比较蓝光增强与白光经尿道膀胱肿瘤电切术。蓝光可能降低复发风险(HR 0.66,95%CI 0.54-0.81,低确定性证据)和进展风险(HR 0.65,95%CI 0.50-0.84,低确定性证据),临床相关性取决于基线风险,未发现严重手术并发症增加。

要点

  • 蓝光经尿道膀胱肿瘤电切术可能降低非肌层浸润性膀胱癌复发风险(HR 0.66,低确定性证据)。
  • 蓝光经尿道膀胱肿瘤电切术可能降低疾病进展风险(HR 0.65,低确定性证据)。
  • 未发现蓝光膀胱镜增加严重手术并发症,但无其他非手术不良事件的试验证据。

核心结论

  • 蓝光经尿道膀胱肿瘤电切术可能对疾病复发和进展风险有有利影响,但风险降低是否具有临床相关性很大程度上取决于患者的基线风险。
  • 未发现蓝光膀胱镜增加严重手术并发症,也未发现关于其他非手术不良事件的试验证据。

研究设计与样本

  • 系统评价与Meta分析,检索多个数据库自建库至2021年3月,纳入16项比较蓝光与白光经尿道膀胱肿瘤电切术的随机对照试验,共4325例参与者,采用随机效应模型,按GRADE方法逐结局评估证据质量。

主要发现

  • 蓝光经尿道膀胱肿瘤电切术可能降低疾病复发风险(HR 0.66,95%CI 0.54-0.81;低确定性证据),取决于基线风险。
  • 对于低危、中危和高危非肌层浸润性膀胱癌患者,与白光经尿道膀胱肿瘤电切术相比,蓝光组每1000例参与者分别减少48例(减少66至27例)、109例(减少152至59例)和147例(减少211至76例)复发。
  • 蓝光经尿道膀胱肿瘤电切术可能降低疾病进展风险(HR 0.65,95%CI 0.50-0.84;低确定性证据),取决于基线风险。
  • 对于低危、中危和高危非肌层浸润性膀胱癌患者,与白光经尿道膀胱肿瘤电切术相比,蓝光组每1000例参与者分别减少1例(减少1至0例)、17例(减少25至8例)和56例(减少81至25例)进展。

局限性

  • 复发和进展结局的证据确定性为低。
  • 未发现关于其他非手术不良事件的试验证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effects of blue-light (BL)-enhanced transurethral resection of bladder tumour (TURBT) compared to white-light (WL)-based TURBT in the treatment of non-muscle-invasive bladder cancer (NMIBC). METHODS: Based on a published protocol, we performed a systematic search of multiple databases from their inception to March 2021. We included randomized controlled trials (RCTs) comparing blue-light (BL) TURBT to white-light (WL) TURBT. Our meta-analysis was based on a random-effects model. We assessed the quality of evidence on a per-outcome basis according to the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach. RESULTS: We included 16 RCTs involving a total of 4325 participants in this review. BL TURBT may reduce the risk of disease recurrence over time (hazard ratio [HR] 0.66, 95% confidence interval [CI] 0.54-0.81; low-certainty evidence) depending on baseline risk. For participants with low-, intermediate- and high-risk NMIBC, this corresponded to 48 (66 fewer to 27 fewer), 109 (152 fewer to 59 fewer) and 147 (211 fewer to 76 fewer) fewer recurrences per 1000 participants when compared to WL TURBT, respectively. BL TURBT may also reduce the risk of disease progression over time (HR 0.65, 95% CI 0.50-0.84; low-certainty evidence) depending on baseline risk. For participants with low-, intermediate- and high-risk NMIBC, this corresponded to 1 (1 fewer to 0 fewer), 17 (25 fewer to 8 fewer), and 56 (81 fewer to 25 fewer) fewer progressions per 1000 participants when compared to WL TURBT, respectively. CONCLUSIONS: Our findings suggest a favourable impact of BL TURBT on the risk of disease recurrence and progression; however, whether this risk reduction is clinically relevant greatly depends on the baseline risk of patients. We did not find an increase in severe surgical complications with BL cystoscopy, and we did not find any trial evidence on other, non-surgical adverse events.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Maisch P, Koziarz A, Vajgrt J, et al. Blue vs white light for transurethral resection of non-muscle-invasive bladder cancer: an abridged Cochrane Review. BJU Int. 2022. PMID: 35238145. doi:10.1111/bju.15723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。